![Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study - The Lancet Rheumatology Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/afd45ccd-ea47-426c-8047-348b5fcae8e1/gr4_lrg.jpg)
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study - The Lancet Rheumatology
![Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/3d07e649-0b63-4adc-a599-94f8023d0fea/gr3_lrg.jpg)
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology
![Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology](https://www.thelancet.com/cms/asset/4e2e36bf-c410-43f7-b070-8f73e53c44cc/gr1.jpg)
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology
![Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study - The Lancet Rheumatology Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/6c19a302-07cc-4439-8955-324faf754098/gr3_lrg.jpg)